Do we need novel radiologic response criteria for brain tumor immunotherapy?

Expert Review of Neurotherapeutics

Volumn 11, Issue 5, 2011, Pages 619-622

  Okada, Hideho ^a   Pollack, Ian F ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

glioma; immunotherapy; radiological response; response criteria; vaccine

Indexed keywords

CANCER VACCINE;

BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INFLAMMATION; RADIOLOGICAL PARAMETERS; REVIEW; TUMOR MICROENVIRONMENT; VACCINATION;

BRAIN NEOPLASMS; HUMANS; IMMUNOTHERAPY; TREATMENT OUTCOME;

EID: 79955667525     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.49     Document Type: Review

References (19)

1. Finn OJ. Cancer immunology. N. Engl. J. Med. 358(25), 2704-2715 (2008).
2. Okada H, Kohanbash G, Zhu X et al. Immunotherapeutic approaches for glioma. Crit. Rev. Immunol. 29(1), 1-42 (2009).
3. Walker DG, Laherty R, Tomlinson FH, Chuah T, Schmidt C. Results of a Phase I dendritic cell vaccine trial for malignant astrocytoma: Potential interaction with adjuvant chemotherapy. J. Clin. Neurosci. 15(2), 114-121 (2008). (Pubitemid 50017630)
4. Wheeler CJ, Black KL, Liu G et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res. 68(14), 5955-5964 (2008).
5. Wheeler CJ, Das A, Liu G, Yu JS, Black KL. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin. Cancer Res. 10(16), 5316-5326 (2004). (Pubitemid 39100466)
6. Okada H, Kalinski P, Ueda R et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with a-type 1 polarized dendritic cells and polyinosinic- polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J. Clin. Oncol. 29(3), 330-336 (2011).
7. Yang I, Huh NG, Smith ZA, Han SJ, Parsa AT. Distinguishing glioma recurrence from treatment effect after radiochemotherapy and immunotherapy. Neurosurg. Clin. N. Am. 21(1), 181-186 (2010).
8. Brandsma D, van den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr. Opin. Neurol. 22(6), 633-638 (2009).
9. Yang I, Aghi MK. New advances that enable identification of glioblastoma recurrence. Nat. Rev. Clin. Oncol. 6(11), 648-657 (2009).
10. Wen PY, Macdonald DR, Reardon DA et al. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J. Clin. Oncol. 28(11), 1963-1972 (2010).
11. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication, Geneva, Switzerland (1979).
12. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl Cancer Inst. 92(3), 205-216 (2000). (Pubitemid 30099779)
13. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 45(2), 228-247 (2009).
14. Henson JW, Ulmer S, Harris GJ. Brain tumor imaging in clinical trials. AJNR Am. J. Neuroradiol. 29(3), 419-424 (2008). (Pubitemid 351424049)
15. Hoos A, Eggermont AMM, Janetzki S et al. Improved endpoints for cancer immunotherapy trials. J. Natl Cancer Inst. 102(18), 1388-1397 (2010).
16. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
17. Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin. Cancer Res. 15(23), 7412-7420 (2009).
18. Sampson JH, Heimberger AB, Archer GE et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28(31), 4722-4729 (2010).
19. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010).